EP0743956A4 - Pretargeting methods and compounds - Google Patents

Pretargeting methods and compounds

Info

Publication number
EP0743956A4
EP0743956A4 EP95904859A EP95904859A EP0743956A4 EP 0743956 A4 EP0743956 A4 EP 0743956A4 EP 95904859 A EP95904859 A EP 95904859A EP 95904859 A EP95904859 A EP 95904859A EP 0743956 A4 EP0743956 A4 EP 0743956A4
Authority
EP
European Patent Office
Prior art keywords
compounds
pretargeting methods
pretargeting
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95904859A
Other languages
German (de)
French (fr)
Other versions
EP0743956A1 (en
Inventor
Louis J Theodore
Donald B Axworthy
John M Reno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of EP0743956A1 publication Critical patent/EP0743956A1/en
Publication of EP0743956A4 publication Critical patent/EP0743956A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP95904859A 1993-12-07 1994-12-07 Pretargeting methods and compounds Withdrawn EP0743956A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16318493A 1993-12-07 1993-12-07
US163184 1993-12-07
PCT/US1994/014172 WO1995015978A1 (en) 1993-12-07 1994-12-07 Pretargeting methods and compounds

Publications (2)

Publication Number Publication Date
EP0743956A1 EP0743956A1 (en) 1996-11-27
EP0743956A4 true EP0743956A4 (en) 1999-03-24

Family

ID=22588842

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95904859A Withdrawn EP0743956A4 (en) 1993-12-07 1994-12-07 Pretargeting methods and compounds

Country Status (4)

Country Link
EP (1) EP0743956A4 (en)
JP (1) JPH09506106A (en)
CA (1) CA2178477A1 (en)
WO (1) WO1995015978A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556982A (en) * 1985-01-14 1996-09-17 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
US6908903B1 (en) 1994-12-07 2005-06-21 Aletheon Pharmaceuticals, Inc. Cluster clearing agents
EP0906015A4 (en) * 1996-06-06 2004-05-12 Neorx Corp Liver retention clearing agents
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
CA2363067C (en) 1999-01-12 2012-03-20 David J. Grainger Compounds and methods to inhibit or augment an inflammatory response
WO2001094347A1 (en) * 2000-06-08 2001-12-13 Lilly Icos Llc Tetracyclic diketopiperazine compounds as pdev inhibitors
US7534431B2 (en) * 2003-01-31 2009-05-19 Immunomedics, Inc. Methods and compositions for administering therapeutic and diagnostic agents
RU2013133813A (en) 2010-12-21 2015-01-27 Конинклейке Филипс Электроникс Н.В. Means for removing biomolecules from the bloodstream

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
WO1992012730A1 (en) * 1991-01-17 1992-08-06 Rune Nilsson A method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose
WO1993015210A1 (en) * 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
WO1993025240A2 (en) * 1992-06-09 1993-12-23 Neorx Corporation Pretargeting methods and compounds
WO1994004702A2 (en) * 1992-08-21 1994-03-03 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin conjugates
WO1995015770A1 (en) * 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
IT1245748B (en) * 1990-12-21 1994-10-14 Mini Ricerca Scient Tecnolog PREPARATION INCLUDING BIOTINYLATE MONOCLONAL ANTIBODIES, AVIDIN AND BIOTIN, FOR DIAGNOSIS OF CANCER DISEASES AND ITS USE

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
WO1992012730A1 (en) * 1991-01-17 1992-08-06 Rune Nilsson A method and a system for enhanced in vivo clearance of diagnostic and/or therapeutic agents by extracorporeal depletion, and the use of said agents for said purpose
WO1993015210A1 (en) * 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
WO1993025240A2 (en) * 1992-06-09 1993-12-23 Neorx Corporation Pretargeting methods and compounds
WO1994004702A2 (en) * 1992-08-21 1994-03-03 Immunomedics, Inc. Improved detection and therapy of lesions with biotin/avidin conjugates
WO1995015979A1 (en) * 1993-12-07 1995-06-15 Neorx Corporation Pretargeting methods and compounds
WO1995015770A1 (en) * 1993-12-09 1995-06-15 Neorx Corporation Pretargeting methods and compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KARACAY H ET AL: "Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Reagent development.", BIOCONJUG CHEM, JUL-AUG 1997, 8 (4) P585-94, UNITED STATES, XP002075839 *
PLUCKTHUN A ET AL: "New protein engineering approaches to multivalent and bispecific antibody fragments", IMMUNOTECHNOLOGY, vol. 3, no. 2, June 1997 (1997-06-01), pages 83-105, XP004126672 *
ROSEBROUGH S. F.: "Two step immunological approaches for imaging and therapy", Q. J. NUCL. MED., vol. 40, September 1996 (1996-09-01), pages 234 - 251, XP002086486 *
See also references of WO9515978A1 *

Also Published As

Publication number Publication date
JPH09506106A (en) 1997-06-17
WO1995015978A1 (en) 1995-06-15
CA2178477A1 (en) 1995-06-15
EP0743956A1 (en) 1996-11-27

Similar Documents

Publication Publication Date Title
EP0736035A4 (en) Pretargeting methods and compounds
GB9422158D0 (en) N-acylindoles and related compounds
DE69400639D1 (en) Rehydratationsgetraenk
DE69401926D1 (en) Hydroxamsäurederivate
GB9419218D0 (en) Methods
EP0732943A4 (en) Three-step pretargeting methods and compounds
DE69406448D1 (en) Luftreinigungsgerät
HU9402884D0 (en) 4-arylamino-benzopyran and related compounds
EP0734398A4 (en) Compounds and methods
DE69405713D1 (en) Carbonylierungsverfahren
DE59407177D1 (en) 2-fluorcycloyhexen-derivate
DE59409705D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
EP0743956A4 (en) Pretargeting methods and compounds
DE59408644D1 (en) Jacquardmaschine
DE69408437D1 (en) Oxychlorierungsverfahren
DE59408733D1 (en) Metallhalogenidentladungslampe
DE59410065D1 (en) 3-methoxy-2-phenyl-acrylsäuremethylester
DE69407946D1 (en) Oxychlorierungskatalysator
GB9315306D0 (en) Methods
GB9315351D0 (en) Methods
GB9315340D0 (en) Methods
DE59407310D1 (en) Phenylazotriazolopyridinfarbstoffe
AU122479S (en) Label-printer
DE69327259D1 (en) Signalmetrikabschätzer
GB9315298D0 (en) Methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19990205

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020416

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEORX CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050208